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1way Anova, 1way analysis of variance; 7-AAD, 7-Aminoactinomycin D; Ad, Adenoviral; GSIS, 
Glucose stimulated insulin secretion; IBMIR, Instant blood mediated inflammatory reaction; 
IGF-II, Insulin-like Growth Factor-II; IGF-1R, Insulin-like Growth Factor-I receptor; IFN-γ, 
Interferon-γ; IL-1β, Interleukin-1β; MAPK, Mitogen-activated kinase, MOI, Multiplicity of 
infection; PI, Propidium Iodide; T1D, Type 1 Diabetes Mellitus; ELISA, enzyme-linked 
immunosorbent assay; GFP, green fluoresence protein; IR, insulin receptor, I.P, intra peritoneal; 
IEQ, islet equivalent; PI3K, phosphatidylinositol-3kinase; pAKT, phospho-akt; PVDF, polyvinyl 
difluoride; rIGF-II, recombinant IGF-II; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel 
electrophoresis; SEM, standard error of the mean; SI, stimulation index; STZ, streptozotocin, 
















Background: The early loss of functional islet mass (50-70%) due to apoptosis following 
clinical transplantation contributes to islet allograft failure. Insulin-like Growth Factor-II 
(IGF-II) is an anti-apoptotic protein that is highly expressed in β-cells during development, 
but rapidly decreases in post-natal life. 
Methods: We used an Adenoviral (Ad) vector to over express IGF-II in isolated rat islets and 
investigated its anti-apoptotic action against exogenous cytokines IL-1β and IFN-γ induced 
islet cell death in vitro. Using an immunocompromised marginal mass islet transplant model, 
the ability of Ad-IGF-II transduced rat islets to restore euglycemia in NOD-SCID diabetic 
recipients was assessed. 
Results: Ad-IGF-II transduction did not affect islet viability or function. Ad-IGF-II cytokine 
treated islets exhibited decreased cell death (40 ± 2.8%) vs. Ad-GFP and untransduced control 
islets (63.2 ± 2.5% and 53.6 ± 2.3%, respectively). Ad-IGF-II over expression during cytokine 
treatment resulted in a marked reduction in TUNEL positive apoptotic cells (8.3 ± 1.4%) vs. 
Ad-GFP control (41 ± 4.2%) and untransduced control islets (46.5 ± 6.2%). Western blot 
analysis confirmed that IGF-II inhibits apoptosis via activation of the PI3K/Akt signalling 
pathway. Transplantation of IGF-II over expressing islets under the kidney capsule of diabetic 
mice restored euglycemia in 77.8% of recipients, compared to 18.2% and 47.5% of Ad-GFP 
and untransduced control islet recipients, respectively (p<0.05 Log-rank (Mantel Cox)). 
Conclusions: Anti-apoptotic IGF-II decreases apoptosis in vitro and significantly improved 
islet transplant outcomes in vivo. Anti-apoptotic gene transfer is a potentially powerful tool to 




Islet transplantation is a promising therapeutic option for Type 1 Diabetes Mellitus (T1D), 
with the ability to improve glycometabolic control in T1D patients and in select cases achieve 
insulin independence (1, 2). While short term glucose stabilization and insulin independence 
rates continue to improve, long-term follow up reveals a marked reduction in islet graft 
function over time (3, 4). The reasons for the decline in insulin independence rates following 
islet transplantation are complex, beginning before pancreas procurement as brain death is 
associated with the production of islet toxic cytokines such as TNF-α, IL-1β and IL-6 (5-7).  
Intraportally transplanted islets reside in the hostile environment of the liver, where they are 
exposed to the instant blood mediated inflammatory reaction (IBMIR) (8), alloimmunity (9), 
recurrence of islet specific autoimmunity (10), a highly toxic pro-inflammatory cytokine 
storm (e.g. IL-1β, IFN-α, IFN-γ and TNF-α) (11, 12) and hypoxia due to inadequate 
revascularization post-transplant (13, 14). All of these stresses contribute to islet apoptosis 
and promote failure of the islet allograft (15). Strategies to prevent early apoptosis are 
therefore highly desirable to enhance long term islet survival.  
 
Insulin-like Growth Factor-II (IGF-II) is a potent growth factor, recognised for its anti-
apoptotic ability in a wide variety of cell types including pancreatic islets (16-18). IGF-II 
binds to the Insulin-like Growth Factor-I receptor (IGF-1R) to mediate its anti-apoptotic 
function, resulting in activation of the phosphatidylinositol-3kinase (PI3K)/Akt pathway (19-
21). IGF-II blocks proteolytic processing of the major executioner caspases, caspase-3 and 
caspase-7 (22, 23), preventing initiation of the apoptotic cascade (24). 
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In this study, the influence of local human IGF-II over expression on rat pancreatic islet cell 
survival in vitro and in vivo was examined. The human IGF-II protein has 85% sequence 
identity to the rat protein. Here we describe successful transduction of rat islets with an 
Adenoviral (Ad)-IGF-II based vector to over express IGF-II, without affecting islet viability 
or function. Over expression of IGF-II in islets resulted in enhanced islet survival in vitro and 
in an in vivo marginal mass islet transplant model, indicating that strategies to combat 


















Transduction efficiency of Ad-GFP and Ad-IGF-II in isolated rat islets 
Ad-GFP was used to transduce isolated rat islets in vitro at multiplicity of infection (MOI) 10, 
100, 200, 500 and 1000, to assess the transduction efficiency of the Ad vector in rat islets. 
Green fluorescence protein (GFP) was included in the Ad-GFP vector to function as a 
transduction marker. At 48 h post-transduction, GFP expression was observed in transduced 
islets, although at different efficiencies depending on the MOI (Figure 1 A). 
Ad-IGF-II transduced rat islets (MOI 100) constitutively produced and secreted 8.9 ± 1.3 ng 
human IGF-II into the cell culture supernatant at 24 h, this increased to 14.3 ng ± 2.4 at 48 h.  
The level of secreted IGF-II reached a maximum of 24.1 ng ± 1 on day 5 (Figure 2). The 
secretion of human IGF-II was observed only in the IGF-II transduced cells demonstrating 
that Ad-IGF-II mediated effective transduction and specific expression of IGF-II in 
transduced islet cells.  
Effect of Ad-IGF-II transduction on islet function and viability 
Islet viability was not adversely affected when transduced with Ad-IGF-II at MOI 100 (74.3% 
± 8.2) compared to untransduced controls (69.2% ± 4.7). However, when rat islets were 
transduced with Ad-GFP there was minor cytotoxicity and as a result of this, islet viability 
was reduced to 58.2% ± 1.8 (Figure 1 B). To determine whether insulin secretion was 
adversely affected in Ad-IGF-II, Ad-GFP or untransduced islets, in vitro islet function was 
characterised by challenging islets with glucose. Transduction of islets with Ad-GFP or Ad-
IGF-II (MOI 100) did not alter the insulin secretory function of islets (1.8 ± 0.4 and 2 ± 0.5 
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stimulation index (SI)) respectively, compared to untransduced islets (2 ± 0.5 SI) (Figure 1 
C). Based on these findings MOI 100 was chosen as the MOI for further experiments. 
Effect of Ad-IGF-II transduction on islet apoptosis in vitro 
To investigate the anti-apoptotic effect of IGF-II, Ad-IGF-II transduced islets were incubated 
with a cocktail of pro-inflammatory cytokines interleukin-1β (IL-1β) and interferon-γ (IFN-γ) 
for 24 h to induce apoptosis. Following cytokine exposure, there was a marked reduction in 
the number of TUNEL positive (apoptotic) cells in the Ad-IGF-II transduced islets compared 
to Ad-GFP transduced islets (Figure 3 A – C). Specifically, 46.5% ± 6.2 and 41% ± 4.2 total 
islet cells in the untransduced and Ad-GFP transduced groups were TUNEL positive, 
respectively. However, when IGF-II was over expressed in islets during cytokine exposure a 
decrease in the number of TUNEL positive apoptotic cells was observed (8.3% ± 1.4), 
p≤0.0001 (1way ANOVA) (Figure 3 D). 
The cytoprotective effect of Ad-IGF-II on islet cell death following cytokine exposure was 
investigated by Annexin V and PI staining. Following cytokine exposure, Ad-IGF-II 
transduced islets and recombinant (r)IGF-II treated islets displayed a decreased level of 
cytokine induced cell death (39.8% ± 2.8 and 41.9 ± 3.3%, respectively) when compared to 
control islets transduced with Ad-GFP (63.2% ± 2.5) or untransduced (53.6% ± 2.3) (Figure 3 
E, p<0.0001), clearly demonstrating the anti-apoptotic effect of IGF-II in vitro.   
To investigate the pathway through which IGF-II works to inhibit apoptosis, rat islets were 
pre-treated with wortmannin, a potent and specific PI3K inhibitor (25) prior to Ad-IGF-II 
transduction. Ad-IGF-II transduced islets displayed increased levels of phospho-Akt (pAkt) 
compared to the control groups and pre-treament of Ad-IGF-II with wortmannin abolished 
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IGF-II stimulated Akt phosphorylation (Figure 4). Thus, indicating that IGF-II inhibits islet 
cell apoptosis through activation of the PI3K/Akt pathway. 
Effect of Ad-IGF-II islet survival and function after transplantation 
To investigate the effect of Ad-IGF-II transduction in an islet transplant setting, a marginal 
mass of islets (50 islet equivalents (IEQ)) were transduced with Ad-GFP, Ad-IGF-II or 
untransduced and transplanted under the kidney capsule of NOD-SCID STZ-induced diabetic 
mice. The in vivo study was limited to 28 days as it is estimated that 50–70% of islets are 
destroyed in the immediate post transplant period by apoptosis (26, 27). 
 
Transplantation of Ad-IGF-II islets resulted in a return to euglycemia in 77.8% of recipients 
(n=9), compared to 18.2% of Ad-GFP and 45.5% of untransduced islet recipients (both n=11) 
(Figure. 5 A), p<0.05 (Log-rank (Mantel Cox) Test. Ad-IGF-II recipient mice stabilized and 
slightly increased their weight following transplantation, while this was not the case for mice 
receiving untransduced or Ad-GFP transduced islet grafts, p<0.0001 (1way ANOVA) (Figure 
5 B). While nephrectomy of the graft bearing kidney was not performed due to ethical 
guidelines, the diabetic state was confirmed by staining the mice pancreata for endogenous 








Apoptosis is a major cause of islet cell loss in the early post-transplant period (28, 29). The 
insulin-like Growth Factors (IGF-I and IGF-II) are mitogenic peptides involved in the 
regulation of apoptosis (23). IGF-II is produced in the pancreas during fetal and neonatal life 
(30), where it is highly expressed in different islet cell populations (including β-cells) (31-33). 
Recently, Hills and colleagues (34) have described IGF-II as a more effective anti-apoptotic 
survival factor than IGF-I in human placental villous cytotrophoblasts. Moreover, Ad-
mediated IGF-I over expression was unable to protect isolated human islets from apoptosis 
induced by a cocktail of pro-inflammatory cytokines, including IL-1β and IFN-γ (35). 
Therefore, in this study, we evaluated the effect of IGF-II over expression on rat pancreatic 
islet cell survival via an ex vivo gene transfer approach. 
Firstly, Ad-IGF-II efficiently transduced rat islets and IGF-II over expression did not affect 
islet viability or physiological function. Ad-GFP islets displayed decreased cell viability 
compared to untransduced control islets. This may be due to the potential cell toxicity 
associated with GFP (36-38). In the same set of experiments, Ad-IGF-II transduced islets 
displayed increased viability compared to control cells, likely due to the anti-apoptotic 
properties of IGF-II. The utility of Ad mediated IGF-II over expression is that IGF-II 
mediates its anti-apoptotic effect via autocrine and paracrine mechanisms, which negates the 
need for every islet cell to express the therapeutic gene. 
In this study, Ad-IGF-II transduced rat islets were protected from apoptosis and cell death 
induced by pro-inflammatory cytokine exposure in vitro and enhanced islet survival in vivo. 
Western blot confirmed that IGF-II inhibits islet apoptosis via activation of the PI3K/Akt 
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intracellular signalling pathway. This result is supported by the well-documented ability of 
IGF-II to prevent apoptosis via activation of the IGF-1R (16, 17, 39). 
Jourdan and colleagues (40) co-encapsulated islets with bio-engineered TM4 cells producing 
IGF-II and found in vitro islet survival and post-transplant outcomes to be improved. 
However, encapsulated islets are unable to revascularize following transplantation, 
exacerbating islet hypoxia and subsequent β-cell death (41, 42). Moreover, the bio-engineered 
TM4 cells permanently over express the IGF-II gene, raising concern as elevated and 
persistent concentrations of IGF-II have been associated with malignancy (43, 44). 
 
Ilieva and colleagues (45) have shown that incubation of hamster islets with pancreatic duct 
conditioned medium containing 34 ng/ml IGF-II, successfully protects islets from apoptosis 
and necrosis that occurs following the islet isolation procedure. Furthermore, the 
supplementation of minimally nutritive (serum-free) medium with 500 ng/ml IGF-II improves 
in vitro islet viability and allows successful transplantation using a smaller number of 
microencapsulated rat islets (46). This beneficial effect is likely a result of the exogenous 
IGF-II improving islet survival following isolation and encapsulation, resulting in a larger 
mass of islets being transplanted in the IGF treatment group. Due to the limited biological half 
life of growth factors, is unlikely that any residual IGF-II transplanted with the encapsulated 
islets would have any significant effect in vivo.  
 
Transplanted islets are vulnerable to stress induced apoptosis prior to engraftment and 
revascularization (26, 27), therefore a major advantage of the present approach is that islets 
are exposed to a constitutively produced supply of anti-apoptotic IGF-II prior to 
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transplantation and during the immediate post-transplant period. Our data confirms the ability 
of IGF-II to promote islet survival in vitro and this was achieved with a 40-fold lower IGF-II 
concentration than that previously used by Robitaille et al (46). These results suggest that 
there is enhanced anti-apoptotic function when IGF-II is over expressed within the local islet 
microenvironment.  
 
Rat islets exhibit a highly controlled and robust insulin secretory response not present in 
mouse islets (47). For this reason, a minimal mass islet transplant of only 50 IEQ was 
sufficient to induce euglycemia in a minimal number of diabetic recipients. Although this 
study has shown a statistically significant improvement in transplant outcomes in Ad-IGF-II 
recipient mice, the small number of transplanted islets prevented post-transplant validation of 
the islet grafts. Despite this, these findings indicate that anti-apoptotic IGF-II decreases 
apoptosis in vitro and improves islet transplant outcomes in vivo.  
 
One of the limitations of our anti-apoptotic strategy is that it targets only apoptosis as a cause 
of islet loss in the early post-transplant period. In addition to being protected against apoptotic 
insults, islets need to be able to resist alloimmunity, recurrent autoimmunity and effectively 
revascularize following transplantation. Multigene vectors that co-express two or three 
transgenes under the direction of a single promoter (48-52) provide a promising alternative to 
overcome this issue. In conclusion, IGF-II over expression in the early post-transplant period 
is a potentially effective anti-apoptotic strategy to improve islet survival and function 




Materials and methods 
Islet isolation and culture 
Female Albino Wistar rats (250 – 300g) were obtained from the Animal Resources Centre 
(Perth, Australia) and were housed in an approved animal care facility (Institute of Medical 
and Veterinary Science, SA Pathology, Adelaide). Animal experiments were conducted in 
accordance with the animal ethics committees of the University of Adelaide and the IMVS 
guidelines. The pancreatic duct was cannulated and the pancreas was inflated with 1 x Hank’s 
Balanced Salt Solution (Invitrogen, Grand Island, NY, USA). The pancreas was digested with 
collagenase X1 (Sigma-Aldrich, St. Louis, MO, USA). The islets were separated from the 
digested pancreas using a Histopaque-1077 (Invitrogen, Grand Island, NY, USA) density 
gradient. Purified islets were handpicked under a microscope and then cultured for 24 h in 
RPMI 1640 (Invitrogen, Grand Island, NY, USA) medium supplemented with 10% fetal 
bovine serum (FBS) (Gibbco, Grand Island, NY, USA) at 37°C and 5% CO2. Islets were 
quantified by dithizone staining using an islet diameter of 150 μm as one IEQ.  
Ad vectors and transduction of rat islets 
Replication-deficient Ad vectors expressing GFP or human IGF-II were purchased from 
Welgen, Inc., Worcester, MA, USA. The gene(s) of interest were controlled by the 
constitutive human cytomegalovirus CMV promoter. The titers of Ad-GFP and Ad-IGF-II 
were both 2 x 10
10
 particle forming units (pfu)/ml. Islets (50 IEQ) were transduced with Ad 
vectors in serum-free RPMI 1640 (Invitrogen, Grand Island, NY, USA) for 4 h at 37°C. 
Following transduction islets were cultured for 48 h in complete RPMI 1640 (Invitrogen, 
Grand Island, NY, USA) containing 10% FBS (Gibbco, Grand Island, NY, USA) prior to 
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experimental assays. Untransduced islets (50 IEQ) underwent the same procedure but were 
not transduced with virus. MOI was calculated based on the assumption that one IEQ contains 
on average 2000 cells (53, 54).   
Analysis of Ad transduction efficiency and islet viability following Ad transduction 
GFP reporter gene expression after Ad-GFP transduction in islets was determined by flow 
cytometry. Viability of dissociated islets following transduction was assessed by staining with 
7-Aminoactinomycin D (7-AAD) (Invitrogen, Grand Island, NY, USA) (5 μg/ml), and 
determined by flow cytometric analysis using a FACS CANTO II (Becton Dickson, San Jose, 
CA, USA).  
Glucose Stimulated Insulin Secretion 
To determine the effect of Ad transduction and/or IGF-II over expression on insulin secretion 
in response to glucose, a static glucose stimulation test was performed with rat islets. Ad-
GFP, Ad-IGF-II or untransduced islets (50 IEQ) were incubated in either 1.2 ml of low (2.8 
mM) or high (25 mM) glucose RPMI 1640 (Invitrogen, Grand Island, NY, USA) at 37°C for 
2 h. Supernatant (1 ml) was collected for insulin analysis and stored at -20°C. Samples were 
diluted 1:10 and then insulin concentrations were measured using a rat insulin enzyme-linked 
immunosorbent assay (ELISA) kit (Mercodia, Uppsala, Sweden). The glucose SI of islets was 
calculated by dividing the insulin response to high glucose incubation by the insulin response 





In vitro determination of IGF-II secretion from Ad-IGF-II transduced islets 
Rat islets (50 IEQ) were divided into three groups comprising 1) untransduced islets, 2) Ad-
GFP transduced islets and 3) Ad-IGF-II transduced islets. To measure IGF-II secretion, rat 
islet supernatant was collected each day for five days and samples were stored at -20°C. 
Samples were diluted 1:10 and then the concentration of IGF-II was analysed using a human 
IGF-II ELISA kit (Life Research Pty Ltd, Victoria, Australia). 
Measuring islet cell death 
To evaluate the effect of IGF-II expression on islet cell death, rat islets (50 IEQ) were 
untransduced, transduced with Ad-GFP, Ad-IGF-II or pre-treated for 2 h with 500 ng/ml 
rIGF-II, human (R&D, Minneapolis, MN, USA) and then treated with pro-inflammatory 
cytokines IL-1β (ProSpecbio, Ness-Ziona, Israel) (35ng/ml) and IFN-γ (Sigma-Aldrich, St. 
Louis, MO, USA) (40ng/ml) for 24 h. Islet cell death was assessed using flow cytometry. The 
islets were dispersed and stained using Annexin V (Invitrogen, Grand Island, NY, USA) (5 
μl) for 15 min at RT. 2 µl Propidium Iodide (PI) (Invitrogen, Grand Island, NY, USA) at 250 
μg/ml was then added to the cell suspension which was then analysed using a FACS CANTO 
II. Apoptosis was determined on islet cytospin preparations using an In Situ Cell Death 
Detection Kit as per manufacturer’s instructions (Roche, Indianapolis, IN, USA). As a 
minimum, each sample was stained in triplicate for six different rat islet preparations and the 
images were produced using a Nikon C1-Z Confocal Microscope. The number of TUNEL-
positive cells (red) within each islet were counted and compared with the total number of 




Western blotting analysis 
Rat islets (50 IEQ) were untransduced, transduced with Ad-GFP, Ad-IGF-II or pre-treated for 
1 h with 200 mM wortmannin (Sigma-Aldrich, St. Louis, MO, USA) prior to Ad-IGF-II 
transduction for 48 h. Following transduction, all experimental groups were treated with pro-
inflammatory cytokines IL-1β (35ng/ml) and IFN-γ (40ng/ml) for 24 h. Islets were harvested 
for western blotting analysis. The protein extracts were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinyl difluoride 
(PVDF) membrane (Millipore, Billerica, MA, USA). The blots were incubated with rabbit 
polyclonal pAkt (Ser473) antibody (1:1000) and rabbit polyclonal Akt antibody (1:1000). 
Blots were then incubated in anti-rabbit IgG, HRP-linked secondary antibody (1:2000). All 
antibodies were purchased from Cell Signalling Technology, Inc., Danvers, MA, USA. The 
bands were detected using a Novex® ECL Chemiluminescent Substrate Reagent Kit 
(Invitrogen, Grand Island, NY, USA). 
Diabetes induction 
Female NOD-SCID mice (9 – 12 weeks) were obtained from the Animal Resources Centre 
(Perth, Australia) and housed in a pathogen-free environment (IMVS, SA Pathology, 
Adelaide). Diabetes was induced in mice by a single intra peritoneal (i.p) injection of 170 – 
180 mg/kg streptozotocin (STZ) (Sigma-Aldrich, St. Louis, MO, USA), freshly dissolved in 
0.1M citrate buffer (pH 4.5). Tail blood was taken from non-fasting animals and blood 
glucose concentrations were measured with an Optium Xceed
TM
 glucometer (Medisense, 
Victoria, Australia). Diabetes was confirmed when blood glucose levels were ≥16.6 mmol/l 
for two consecutive days (55, 56). 
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Marginal mass islet transplantation 
Diabetic recipients received a marginal mass islet transplant (50 IEQ) of Ad-GFP (MOI 100), 
Ad-IGF-II (MOI 100) or untransduced islets under the left kidney subcapsular space. Reversal 
of diabetes was defined as blood glucose ≤11.2 mmol/l for two consecutive days (56). 
Statistical analysis 
Values were given as data ± standard error of the mean (SEM) and compared using one-way 
analysis of variance (1way ANOVA) followed by Bonferroni’s multiple comparison test, with 
*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001, where appropriate (GraphPad Prism 
software 5, Inc, San Diego, CA). Densitometry of western blots was performed using ImageJ 
software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, 
USA). Log-rank (Mantel Cox) analysis was used in the minimal islet mass model (StataCorp. 
2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP). For all 
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Figure. 1. Evaluation of Ad transduction on rat islets In Vitro. (A) Rat islets were 
transduced with Ad-GFP at MOI 10, 100, 200, 500 and 1000 or left untransduced (control). 
Flow cytometry was used to determine percent GFP expression in dispersed islet cells. Data 
are the mean ± SEM of three independent experiments. There was no significant difference in 
GFP expression amongst the groups transduced with Ad-GFP (p=0.06) (1way ANOVA). (B) 
Rat islets were transduced with Ad-GFP (MOI 100), Ad-IGF-II (MOI 100) or left 
untransduced (control). Flow cytometry 7-AAD staining was used to determine the viability 
in dispersed islet cells. Data are the mean ± SEM of three (Ad-IGF-II) or two (Ad-GFP) 
independent experiments, p=0.322 (1way ANOVA). (C) Rat islets were transduced with Ad-
GFP (MOI 100), Ad-IGF-II (MOI 100) or untransduced (control) and then subject to GSIS. 
Insulin ELISA was used to determine the stimulation index in experimental samples. Data are 
the mean ± SEM of five independent experiments, p=0.903 (1way ANOVA).  
Figure. 2. Time course of human IGF-II secretion from Ad-IGF-II transduced rat islets 
in vitro. Rat islets were transduced with Ad-GFP MOI 100, Ad-IGF-II MOI 100 or 
untransduced (control). Secreted IGF-II levels in the medium were measured using a human 
IGF-II ELISA. Error bars are the data ± SEM for three (days 3, 4 and 5) or nine (days 1 and 2) 
replicate experiments, ****p<0.0001 (1wayANOVA). Bonferroni Multiple Comparison Test: 
**p<0.01 Ad-GFP transduced islets vs. Ad-IGF-II Day 1 transduced islets, ****p<0.0001 
Ad-GFP transduced islets vs. Ad-IGF-II day 2-5 transduced islets. 
Figure. 3. Anti-apoptotic investigation of Ad-IGF-II transduced islets following pro-
inflammatory cytokine exposure. Islets were left untreated or transduced at MOI 100 with 
Ad-GFP, Ad-IGF-II or untransduced 48 h before addition of IL-1β (35ng/ml) and IFN-γ (40 
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ng/ml) for an additional 24 h, or islets were pre-treated for 2 h with rIGF-II (500 ng/ml) 
before addition of pro-inflammatory cytokines. (A-D) TUNEL staining was used to determine 
islet cell apoptosis.  Representative images of Untransduced, Ad-GFP and Ad-IGF-II TUNEL 
stained islets are depicted in A – C respectively. TUNEL positive cells (red) in the fluorescent 
images correspond to apoptotic cells. Blue = DAPI nuclear stain. Images were taken at 20 x 
magnification, Scale bar = 50µm. (D) A total of 25 untreated islets, 22 untransduced islets, 
and 32 Ad-GFP or Ad-IGF-II transduced islets from six different rat islet preparations were 
counted to quantify the number of apoptotic cells. The percentage of apoptotic islets was 
calculated by dividing the number of TUNEL positive islets by total islet cells. Data are mean 
± SEM, ****P<0.0001 (1way ANOVA). Bonferroni Multiple Comparison Test: 
****p<0.0001 Untreated islets vs. Untransduced islets, ****p<0.0001 Untreated islets vs. 
Ad-IGF-II transduced islets, ****p<0.0001 Untransduced vs. Ad-IGF-II transduced islets, 
****p<0.0001 Ad-GFP transduced islets vs. Ad-IGF-II transduced islets. (E) Flow cytometry 
was used to determine percent islet cell death of dispersed islet cells using Annexin V and PI 
staining. The data is expressed as ± SEM of five independent experiments, ***p<0.0001 
(1wayANOVA). Bonferroni Multiple Comparison Test: ***p<0.001 Untreated islets vs. 
Untransduced islets, ****p<0.0001 Untreated islets vs. Ad-GFP transduced islets, *p<0.05 
Untransduced vs. Ad-IGF-II transduced islets, ***p<0.001 Ad-GFP transduced islets vs. 500 
ng/ml rIGF-II islets, ***p<0.001 Ad-GFP transduced islets vs. Ad-IGF-II transduced islets.  
Figure. 4. IGF-II signals through the PI3K/Akt pathway to inhibit apoptosis. Western 
blot of islets untreated, untransduced or transduced at MOI 100 with Ad-GFP or Ad-IGF-II 
for 48 h, before addition of IL-1β (35 ng/ml) and IFN-γ (40 ng/ml) for an additional 24 h. 
Islets were also treated with wortmannin (200 mM) for 1 h prior to Ad-IGF-II transduction 
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and cytokine treatment. Phospho-Akt (pAKT) levels were determined by densitometry (above 
pAKT blot) and corrected for total Akt levels relative to the untransduced islet control lane. 
Wortmannin treatment of Ad-IGF-II transduced islets reduced the phosphorylation of Akt, 
indicating that IGF-II activates the PI3K/Akt pathway to inhibit apoptosis. 
Figure. 5. Return to euglycemia in STZ-induced diabetic recipients of a marginal mass 
islet graft. Diabetes was induced in immunocompromised NOD-SCID mice by STZ 
injection. Diabetic mice were transplanted with Ad-IGF-II (n=9), Ad-GFP (n=11) or 
untransduced (n=11) marginal mass islet grafts and followed for a maximum of 28 days. (A) 
Return to euglycemia post-transplantation was defined as blood glucose ≤11.2 mmol/l for two 
consecutive days and was achieved in 77.8% of recipients receiving Ad-IGF-II transduced 
islets (7/9) (solid line) compared with 18.2% (2/11) and 45.5% (5/11) of control animals 
receiving Ad-GFP (broken line) or untransduced islets (dotted line), respectively. p<0.05 
(Log-rank (Mantel Cox) Test. Bonferroni Multiple Comparison Test: *p<0.05 Ad-GFP vs. 
Ad-IGF-II. (B) Mice were weighed prior to STZ injection (SW= starting weight) and then 
daily for 28 days following their transplant. Data are the mean ± SEM. ****p<0.0001 (1way 
ANOVA). Bonferroni Multiple Comparison Test: ****p<0.0001 Control vs. Ad-IGF-II, 
****p<0.0001 Ad-GFP vs. Ad-IGF-II. 
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